Reviewing Masimo Corporation (MASI) and Apollo Endosurgery (APEN)
Masimo Corporation (NASDAQ: MASI) and Apollo Endosurgery (NASDAQ:APEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
This table compares Masimo Corporation and Apollo Endosurgery’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
83.2% of Masimo Corporation shares are held by institutional investors. Comparatively, 8.9% of Apollo Endosurgery shares are held by institutional investors. 16.6% of Masimo Corporation shares are held by company insiders. Comparatively, 74.2% of Apollo Endosurgery shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Masimo Corporation has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Masimo Corporation and Apollo Endosurgery, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Masimo Corporation currently has a consensus price target of $97.00, suggesting a potential upside of 12.01%. Apollo Endosurgery has a consensus price target of $11.00, suggesting a potential upside of 100.87%. Given Apollo Endosurgery’s stronger consensus rating and higher probable upside, analysts clearly believe Apollo Endosurgery is more favorable than Masimo Corporation.
Valuation & Earnings
This table compares Masimo Corporation and Apollo Endosurgery’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Masimo Corporation||$730.06 million||6.16||$182.11 million||$6.14||14.10|
|Apollo Endosurgery||$63.01 million||1.50||-$10.53 million||N/A||N/A|
Masimo Corporation has higher revenue and earnings than Apollo Endosurgery.
Masimo Corporation beats Apollo Endosurgery on 9 of the 12 factors compared between the two stocks.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
Receive News & Stock Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related stocks with our FREE daily email newsletter.